Laurent Pharmaceuticals is a private biopharmaceutical company developing a clinical stage, orally-active drug candidate with potential to modulate the immuno-inflammatory response in Cystic Fibrosis patients.


Larry Lands, M.D., Ph.D.
Larry C. Lands, M.D., Ph.D., professor of Pediatrics at McGill University, is director of Pediatric Respiratory Medicine and Director of the Pediatric Cystic Fibrosis Clinic at the Montreal Children’s Hospital-McGill University Health Centre. He is the cystic fibrosis consultant to the Quebec Lung Transplant Program at Centre Hospitalier de Université de Montréal-Hôpital Notre Dame. He has played leadership roles in both the American and Canadian Thoracic Societies and Cystic Fibrosis Canada. Dr. Lands’ expertise is in translational research related to inflammation, nutrition, and functional ability in children and adults with cystic fibrosis. He is co-discoverer of fenretinide for cystic fibrosis with Dr. Danuta Radzioch. He is internationally recognized for his work related to modulation of inflammation and exercise limitation in cystic fibrosis. His research program involves both fundamental and clinical studies in both children and adult aimed at bolstering immune defenses and functional ability in chronic lung diseases, such as cystic fibrosis and asthma. Dr. Lands received his M.D. from McGill University and his Ph.D. from McMaster University. He completed his residency and fellowship in pediatric pulmonology at the Montreal Children’s Hospital-McGill University Health Centre and has been on faculty since 1992.
Read More »
Michael W. Konstan, M.D.
Dr. Konstan is the Chairman of the Department of Pediatrics at University Hospitals Case Medical Center’s Rainbow Babies & Children’s Hospital and Case Western Reserve University School of Medicine where he has been a clinical and academic leader for 25 years. His innovative work has led to novel therapies, early detection through newborn screening and extending significantly the lives of children with Cystic Fibrosis. An internationally renowned physician-scientist specializing in cystic fibrosis, Dr. Konstan’s research has been funded by the Cystic Fibrosis Foundation, the FDA, the National Institutes of Health, and numerous pharmaceutical and biotechnology companies focused on developing therapeutics for the treatment and cure of cystic fibrosis. He has been the lead investigator on several national and international clinical trials that have led to the approval of new therapeutics for cystic fibrosis. Dr. Konstan has published more than 150 peer-reviewed papers in leading medical journals reporting basic and clinical research related to cystic fibrosis, as well as more than a dozen textbook chapters. He has presented more than 200 abstracts at scientific meetings and conferences, both nationally and internationally. He also is a reviewer for numerous peer-reviewed journals, including the Journal of the American Medical Association, Lancet, and the New England Journal of Medicine. In 2013, Dr. Konstan was awarded the Case Western Reserve Medal for Excellence in Health Science Innovation by the School of Medicine. He is a member of the American Pediatric Society, American Academy of Pediatrics, American Thoracic Society, and Society for Pediatric Research.
See More »
Steven Freedman, M.D., Ph.D.
Steven D. Freedman, M.D., Ph.D., is director of the Pancreas Center at Beth Israel Deaconess Medical Center (BIDMC), chief of the Division of Translational Research, and professor of medicine at Harvard Medical School. He has played a leadership role in clinical translational research both at Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Freedman’s expertise is in exocrine pancreatic disease with a particular focus on pancreatitis and cystic fibrosis in both adults and children. He is an internationally recognized leader in these areas with an extensive research program that encompasses both basic science as well as clinical trials of new therapies for pancreatitis, primary sclerosing cholangitis and cystic fibrosis. His collaborative work with Dr. Camilia Martin in the department of neonatology at BIDMC has led to new insights into how fatty acids and nutrition may predispose preterm infants to chronic lung disease and infection. Dr. Freedman has also developed a major focus on health care delivery reform that addresses structuring the doctor-patient encounter to build informed partnerships leading to sustained improvements in health outcomes. Dr. Freedman holds a Ph.D. from Yale University School of Medicine and an M.D. from the University of Connecticut. He completed his residency and fellowship in gastroenterology at Beth Israel Hospital and has remained on faculty since 1991.
Go »
Elias Matouk, MB ChB, FRCPC
Dr. Elias Matouk is the Medical Director of the Adult CF Clinic of McGill University Health Centre at the Montreal Chest Institute and an Associate Professor of Medicine at McGill University. He has over 37 years clinical expertise in caring for adult patients with cystic fibrosis and he is an expert is describing and applying a clinical scoring system which allows capturing clinical disease activity and severity among CF patients. Dr. Matouk is member of Cystic Fibrosis Translational Research Centre (CFTRc), which works with industrial partners to develop new therapeutics for cystic fibrosis.
Camilia Martin, MD
Camilia R. Martin, M.D., M.S., is an assistant professor of pediatrics at Harvard Medical School, and the associate director of the Neonatal Intensive Care Unit and director for Cross-Disciplinary Research Partnerships in the division of translational research at Beth Israel Deaconess Medical Center (BIDMC). Dr. Martin’s research interests are focused on neonatal nutrition and its impact on health and disease in the preterm infant. She has participated in multisite clinical trials, serving as the principal investigator at BIDMC and resulting in publications evaluating growth and long-term neurodevelopmental outcomes in the extremely preterm infant. In 2009, Dr. Martin received a Faculty Fellowship Award from the Program for Faculty Development and Diversity from Harvard Catalyst/Harvard Medical School facilitating her transition from general epidemiology to translational research. Her current research focus is on fat digestion and fatty acid metabolism, postnatal intestinal adaptation, development of local and systemic immune defenses, and regulation of the inflammatory response. Additionally, Dr. Martin is working with Dr. Steven Freedman on a health care delivery model that focuses on structuring the doctor-patient interaction and providing a roadmap to health. Dr. Martin holds an M.D. from Cornell University School of Medicine and a master’s in epidemiology from Harvard School of Public Health. She completed her internship and residency at Children’s Memorial Hospital/Northwestern School of Medicine, where she also served as chief pediatric resident in 1996. Dr. Martin completed her fellowship in perinatal-neonatal medicine at the Harvard Combined Program in Neonatology.